Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Systemic Lupus Erythematosus
NCT04077684Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2019
- Primary completion
- Mar 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in systemic lupus erythematosus (SLE), sponsored by Peking University People's Hospital. Started Sep 2019; status: completed.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04077684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077684.